TJX earnings beat, Revenue misses in Q2
Investing.com - TJX (NYSE:TJX) reported on Wednesday second quarter {{erl-8227||earnings that beat analysts' forecasts and revenue that fell short of expectations. TJX announced earnings...
Neutral
or
Novavax News & Analysis
-
-
US envoy, Novovax CEO hail role played by India and SII during COVID-19 pandemic
The delegates noted the critical role played by US-India cooperation in addressing the COVID-19 pandemic and other global health challenges. They welcomed the partnership between Novavax and...
-
Indian Finance Minister Issues Warnings Regarding Crypto
The Indian finance minister suggested against using cryptocurrency.The law enforcement organization blocked the assets of two crypto exchanges.At a BJP Economic Cell event on Saturday,...
-
Novavax Seeks FDA Emergency Use Nod For Its COVID-19 Vaccine Booster
Novavax Inc (NASDAQ: NVAX) has submitted an application to the FDA for Emergency Use Authorization (EUA) for its protein-based COVID-19 vaccine as a homologous and heterologous booster in...
-
Novavax submits FDA application for its COVID-19 booster
Novavax Inc. said Monday that it asked the Food and Drug Administration to authorize its COVID-19 booster for adults. The company's primary series of protein-based shots received FDA...
-
Biotech ETFs Slip After Novavax Cuts 2022 Guidance
Biotechnology sector-related exchange traded funds retreated with Novavax Inc. (NasdaqGS: NVAX), plunging after the vaccine developer cut its 2022 revenue guidance in half. On Tuesday, the...
-
U.S. CPI, Tesla Stock Sale, Disney Results, EIA Stocks - What's Moving Markets
By Peter Nurse Investing.com -- The main focus of the day will be the release of the latest U.S. consumer price data and the potential impact this has on Fed thinking. Elon Musk’s...
-
Novavax tumbles 31% as waning COVID vaccine demand hits revenue forecast
(Reuters) – U.S. vaccine maker Novavax slumped nearly 31% on Tuesday as falling demand for its COVID-19 shot from low- and middle-income nations led the company to cut its annual revenue...
-
Pre-Open Movers: Nielsen Climbs 20%, AppLivin Makes Offer for Unity
BBQ Holdings Inc (NASDAQ:BBQ) +46%; entered into a definitive merger agreement under which MTY would acquire all of the issued and outstanding common shares of BBQ Holdings for cash...
-
Novavax Crashes 30% After a Deep Guidance Cut, Analyst 'Frustrated'
By Senad Karaahmetovic Shares of Novavax (NASDAQ:NVAX) crashed almost 33% in premarket Tuesday trading after the company cut its full-year revenue guidance. For the second quarter,...
-
Dow Futures Down 15 Pts in Subdued Trading; Novavax Slumps
By Peter Nurse Investing.com -- U.S. stocks are seen opening in a subdued fashion Tuesday, with investors awaiting more corporate earnings results as well as the release of a key...
-
Dow Futures Tick Higher, Novavax Sheds 33.6% After Earnings
By Oliver Gray Investing.com - U.S. stock futures were slightly higher during Monday’s evening deals, after major benchmark averages finished mixed during regular trading as market...
-
After-Hours Movers: Novavax Sinks Over 30%, GoodRx and Lemonade Climb
GoodRx Holdings, Inc. (GDRX) +34%; Revenue for the quarter came in at $191.8 million versus the consensus estimate of $185.36 million.Lemonade (LMND) +13%; reported Q2 EPS of ($1.10), $0.23...
-
Novavax Misses Q2 EPS by $12.03, Cuts FY Guidance
Novavax (NASDAQ:NVAX) reported Q2 EPS of ($6.53), $12.03 worse than the analyst estimate of $5.50. Revenue for the quarter came in at $186 billion versus the consensus estimate of $1.02...
-
Senate Passes Flagship Bill, CVS/Signify, SoftBank Loss - What's Moving Markets
By Geoffrey Smith Investing.com -- U.S. stocks are set to open higher after the Democrats' long-awaited and much-diluted tax and spending bill finally cleared the Senate at the weekend. A...
-
Coronavirus Update: Official U.S. tally of new cases may be declining, but at-home testing obscures data; Novavax opens trial of vaccine for very young children
The daily average for new U.S. cases may have started to decline based on official numbers, but it's unclear at this time if the trend is real as so many people are testing at home and the...
-
Novavax Starts Late-Stage COVID-19 Vaccine Study In Children Below 11 Years
Novavax Inc (NASDAQ: NVAX) has initiated its Phase 2b/3 Hummingbird trial to evaluate the safety, effectiveness, and efficacy of two doses of the Novavax COVID-19 vaccine in children aged...
-
EU says Novavax COVID vaccine should carry heart side-effect warning
LONDON (Reuters) -The European Medicines Agency (EMA) is recommending Novavax’s COVID-19 vaccine carry a warning of two inflammatory conditions of the heart, based on a small number of...
-
Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents
Novavax Inc's (NASDAQ: NVAX) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine received expanded manufacturing and marketing approval in Japan for adolescents aged 12 through 17. Novavax has...
-
Novavax's COVID-19 vaccine is authorized for teens in Australia and Japan
Novavax Inc. said Tuesday that its COVID-19 vaccine received authorization in Australia and Japan for teens. Both authorizations are for adolescents between the ages of 12 and 17 years old....
-
-
US CDC recommends Novavax's Covid-19 vaccine for adults, says report
The US Centers for Disease Control and Prevention (CDC) has endorsed recommendation that Novavax's Covid-19 vaccine be used as another primary series option for adults aged 18 years and...
-
The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Advisory Committee Recommends Novavax's COVID-19 Vaccine For Adults The U.S. Centers for...
-
CDC Advisory Committee Recommends Novavax's COVID-19 Vaccine For Adults
The U.S. Centers for Disease Control and Prevention's (CDC) advisory committee recommended using Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine as a two-dose primary series for individuals...
-
Coronavirus tally: CDC OKs Novavax vaccine, adding fourth alternative -- and more conventional shot -- to U.S. program
The Centers for Disease Control and Prevention authorized the Novavax [s:nvax] vaccine late Tuesday, lifting the final regulatory hurdle for the nation's fourth vaccine, which is based on...
-
The U.S.’s woefully low COVID vaccination rate makes it Novavax’s most appealing market yet
The CDC approved Novavax's COVID vaccine on Tuesday, and investors sent Novavax's stock up 11.5%
-
CDC endorses Novavax COVID shot for adults, adding to the number of vaccine options
CDC officials said between 26 million and 37 million adults haven’t had a single dose -- the population that Novavax, for now, will be targeting.
-
U.S. CDC advisers back Novavax COVID vaccine for adults
By Mrinalika Roy (Reuters) -Advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Tuesday voted unanimously to recommend use of Novavax Inc’s COVID-19 vaccine for...
-
CDC committee recommends Novavax's COVID-19 vaccine
Shares of Novavax Inc. jumped 11.9% in trading on Tuesday after the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted in favor of the company's...
-
CDC panel unanimously recommends Novavax Covid-19 vaccine for adults
Novavax uses different technology than Pfizer and Moderna. U.S. health officials hope Novavax's shots might convince skeptics to get vaccinated.
-
Novavax's Covid-19 Vaccine Wins CDC Advisers' Backing
The newly authorized shot will become widely available if the Centers for Disease Control and Prevention follows the advice of its advisers and recommends the vaccine.
-
Coronavirus tally: CDC panel to discuss Novavax vaccine in move expected to remove final regulatory block to its use
An advisory panel to the Centers for Disease Control and Prevention will meet later Tuesday to discuss the Novavax [s:nvax] vaccine that recently won authorization from the Food and Drug...
-
Serum Institute gets USFDA nod to export Novavax covid jab to US
The USFDA approval makes SII - the first Indian vaccine maker to export vaccines to the US market, a testimony to the company's abilities to produce vaccines under stringent quality...
-
-
Why Novavax Shares Are Plunging Today Despite Much Awaited FDA Emergency Nod?
The European Medicines Agency identified severe allergic reactions as potential side effects of Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine. A few cases of anaphylaxis have been reported...
-
Coronavirus Update: Protein-based vaccine’s OK fails to boost Novavax stock
Coronavirus Update: Protein-based vaccine’s OK fails to boost Novavax stock
-
Coronavirus Update: Novavax’s protein-based vaccine approval fails to boost stock as demand for shots and boosters remains low
U.S. health regulators authorized the use of Novavax Inc.'s COVID-19 vaccine, providing a new option that works differently than the two leading vaccines based on mRNA technology, but the...
-
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Novavax Receives Much Awaited FDA Nod For Protein-Based COVID-19 Vaccine The FDA granted...
-
US regulators OK new COVID-19 shot option from Novavax
Novavax makes a more traditional type of shot than the three other COVID-19 vaccines available for use in the US -- and one that's already available in Europe and multiple other...
-
After FDA’s Approval, Novavax Inches Closer to Introducing COVID-19 Vaccine
Novavax, Inc. (NASDAQ: NVAX) is on the verge of launching its COVID-19 vaccine for individuals 18 years and above. The U.S. Food and Drug Administration (FDA) granted emergency use...
-
Coronavirus tally: FDA approves Novavax vaccine at time when uptake of shots and boosters is low
U.S. health regulators authorized the use of Novavax Inc.'s COVID-19 vaccine, providing a new option that works differently than the two leading vaccines, but at a time when overall demand...
-
A ‘breadth of protection:’ Novavax’s newly-approved COVID vaccine arms the U.S. with a new weapon against Omicron BA.5 subvariant
Novavax says its vaccine prompted 'broad immune responses' against all COVID variants, including BA.5, in clinical data.
-
Novavax vaccine gets authorisation for emergency use in adults from USFDA
The US Food and Drug Administration (FDA) has issued an emergency use authorisation (EUA) for the Novavax Covid-19 vaccine in individuals 18 years of age and older
-
Novavax's COVID Vaccine Finally Approved in the US as Cases Rise, Pfizer and Moderna Dip
By Vlad Schepkov It’s official! The U.S. Food and Drug Administration (FDA) has at last given its affirmative nod to what is now the 4th officially approved COVID-19 vaccine in the United...
-
Midday Movers: Twitter, Delta Air, Novavax and More
By Liz Moyer Investing.com -- U.S. stocks wobbled on Wednesday after a higher-than-expected reading on June inflation. Here are the midday movers for July 13: Twitter Inc (NYSE:TWTR)...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
